Analyst: Wegovy prescriptions in US signal strong start to 2023
Novo Nordisk’s obesity treatment, Wegovy, is off to a great start in 2023, says Senior Equity Analyst Søren Løntoft Hansen at Danish bank Sydbank, looking at the latest prescription figures from Symphony Health Solutions.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Norway denies Novo Nordisk reimbursement for obesity drug
For subscribers